Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $134.80

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $136.4444.

Several equities analysts recently issued reports on TMDX shares. Evercore ISI began coverage on TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, October 18th.

Insider Buying and Selling

In related news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,062 shares of company stock valued at $1,797,634 in the last three months. 7.00% of the stock is currently owned by insiders.

Institutional Trading of TransMedics Group

A number of large investors have recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in TransMedics Group in the second quarter worth approximately $26,000. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in shares of TransMedics Group during the 3rd quarter worth $28,000. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group during the third quarter worth $29,000. Finally, Smartleaf Asset Management LLC increased its holdings in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after buying an additional 135 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Trading Down 0.7%

Shares of TMDX stock opened at $126.79 on Tuesday. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $156.00. The firm has a market cap of $4.33 billion, a PE ratio of 51.33 and a beta of 2.06. The company has a 50-day moving average of $126.72 and a two-hundred day moving average of $123.09. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period in the prior year, the business posted $0.12 EPS. The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. On average, analysts predict that TransMedics Group will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.